NOVARTIS PULLS AD

Novartis has pulled its TV ad for Lamisil from the air after receiving a letter from the FDA objecting to the sequence in which Novartis presents the qualifying and efficacy information for its anti-fungal.

Related Videos
Related Content

25.1% of Patients Cited “Less Noticeable” Vitiligo in Recent Study

March 21st 2023

The Cutaneous Connection: Managing Atopic Dermatitis With Emerging Techniques

March 9th 2023

Indoor Tanning and Melanoma

March 21st 2023

The Cutaneous Connection- Episode 35: QRPs and the Dermatology Practice

December 2nd 2021

Oral Ivarmacitinib Demonstrates Significant Atopic Dermatitis Improvement

March 21st 2023

Annual Meeting Session Highlights Clinical Pearls in Medical Dermatology

March 21st 2023

25.1% of Patients Cited “Less Noticeable” Vitiligo in Recent Study

March 21st 2023

The Cutaneous Connection: Managing Atopic Dermatitis With Emerging Techniques

March 9th 2023

Indoor Tanning and Melanoma

March 21st 2023

The Cutaneous Connection- Episode 35: QRPs and the Dermatology Practice

December 2nd 2021

Oral Ivarmacitinib Demonstrates Significant Atopic Dermatitis Improvement

March 21st 2023

Annual Meeting Session Highlights Clinical Pearls in Medical Dermatology

March 21st 2023

25.1% of Patients Cited “Less Noticeable” Vitiligo in Recent Study

March 21st 2023

The Cutaneous Connection: Managing Atopic Dermatitis With Emerging Techniques

March 9th 2023

Indoor Tanning and Melanoma

March 21st 2023

The Cutaneous Connection- Episode 35: QRPs and the Dermatology Practice

December 2nd 2021

Oral Ivarmacitinib Demonstrates Significant Atopic Dermatitis Improvement

March 21st 2023

Annual Meeting Session Highlights Clinical Pearls in Medical Dermatology

March 21st 2023
© 2023 MJH Life Sciences

All rights reserved.